GlaxoSmithKline
NEWS
As Britain’s “Brexit” from the European Union moves closer and closer, the European Medicines Agency (EMA), the equivalent to the U.S. Food and Drug Administration (FDA), temporary halted some of its activities in preparation.
Cambridge, Massachusetts-based Epizyme emphasized its efforts to move tazemetostat back into clinical trials in its second-quarter financial report.
Laekna, headquartered in Shanghai, China, signed a deal with Novartis Pharma AG for exclusive worldwide rights to two oral Novartis clinical-stage cancer drugs.
Fearing disruption of drug inventories when Brexit takes place, Sanofi, AstraZeneca and Novartis have indicated they are stockpiling drugs.
AstraZeneca’s second-quarter report had a mix of good news and bad news. On the good news side, oncology sales rocketed 37 percent, with strong sales of Lynparza, Tagrisso and Imfinzi. On the bad news side, the company’s selumetinib failed another clinical trial.
Since taking over the helm of GlaxoSmithKline, Emma Walmsley has been driving changes at the company with a heavy focus on pharma R&D. Today, Walmsley and R&D Head Hal Barron unveiled a long-term plan for R&D that is focused on the immune system and genetics.
Months after GlaxoSmithKline unveiled positive long-term data that showed Nucala is an effective treatment for patients with severe asthma, a U.S. FDA staff report is casting doubts on its potential as a treatment for chronic obstructive pulmonary disease (COPD).
GlaxoSmithKline continues to make headway in the development of two-drug regimens to benefit HIV patients – even those who have high levels of the virus.
Nearly four months after acquiring 100 percent control of its consumer health unit, GlaxoSmithKline Chairman Philip Hampton may be pushing for the business to become a standalone entity apart from its pharma and vaccines division, according to The Financial Times.
JOBS
IN THE PRESS